Literature DB >> 2157026

Multidrug resistance associated with altered topoisomerase II activity--topoisomerases II as targets for rational drug design.

C S Morrow1, K H Cowan.   

Abstract

Mesh:

Substances:

Year:  1990        PMID: 2157026     DOI: 10.1093/jnci/82.8.638

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  N-myc amplification and its relationship to experimental therapy.

Authors:  A Livingstone; R J Mairs
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.

Authors:  B Schott; D Londos-Gagliardi; C Ries; S Huet; J Robert
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Morphonuclear characterization of drug resistance by means of digital cell-image analysis: an in vitro assessment.

Authors:  O Pauwels; R Kiss
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.

Authors:  S Houlbrook; C M Addison; S L Davies; J Carmichael; I J Stratford; A L Harris; I D Hickson
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

5.  P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.

Authors:  S Huet; B Schott; J Robert
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.